Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for KRAS lung cancer: combo aims to stop recurrence

NCT ID NCT07431827

First seen Mar 03, 2026 · Last updated Jun 19, 2026 · Updated 20 times

Summary

This Phase 3 trial tests whether adding the targeted drug calderasib to standard immunotherapy (pembrolizumab) can prevent lung cancer from returning in people with a specific KRAS mutation (G12C) after surgery. About 400 participants will receive either the combination or a placebo plus immunotherapy. The main goal is to see how long they stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi ( Site 1825)

    RECRUITING

    Ankara, 06280, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Ankara Bilkent Şehir Hastanesi ( Site 1811)

    RECRUITING

    Ankara, 06800, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Asan Medical Center ( Site 3600)

    RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-••••

  • Athens Medical Center ( Site 1202)

    RECRUITING

    Athens, Attica, 151 25, Greece

    Contact Phone: •••-•••-••••

  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 1904)

    RECRUITING

    Cherkasy, Cherkasy Oblast, 18009, Ukraine

    Contact Phone: •••-•••-••••

  • Centre de Cancérologie du Grand Montpellier ( Site 1016)

    RECRUITING

    Montpellier, Languedoc-Roussillon, 34070, France

    Contact Phone: •••-•••-••••

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309)

    RECRUITING

    CABA, C1431FWO, Argentina

    Contact Phone: •••-•••-••••

  • Chongqing University Three Gorges Hospital ( Site 2138)

    RECRUITING

    Chongqing, Chongqing Municipality, 404199, China

    Contact Phone: •••-•••-••••

  • Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio ( Site 1900)

    RECRUITING

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

    Contact Phone: •••-•••-••••

  • Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 1903)

    RECRUITING

    Vinnytsia, Vinnytsia Oblast, 21029, Ukraine

    Contact Phone: •••-•••-••••

  • Communal noncommercial enterprise of Lviv regional council "Lviv oncological regional therapeutical ( Site 1908)

    RECRUITING

    Lviv, Lviv Oblast, 79031, Ukraine

    Contact Phone: •••-•••-••••

  • Evangelismos General Hospital of Athens ( Site 1204)

    RECRUITING

    Athens, Attica, 106 76, Greece

    Contact Phone: •••-•••-••••

  • Guangxi Medical University Cancer Hospital ( Site 2115)

    RECRUITING

    Nanning, Guangxi, 530200, China

    Contact Phone: •••-•••-••••

  • H.R.U Malaga - Hospital General ( Site 1708)

    RECRUITING

    Málaga, 29010, Spain

    Contact Phone: •••-•••-••••

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1707)

    RECRUITING

    Madrid, 28223, Spain

    Contact Phone: •••-•••-••••

  • Hacettepe Universite Hastaneleri ( Site 1810)

    RECRUITING

    Ankara, 06410, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Hospital Clinico San Carlos ( Site 1706)

    RECRUITING

    Madrid, 28040, Spain

    Contact Phone: •••-•••-••••

  • Hospital Insular de Gran Canaria ( Site 1704)

    RECRUITING

    Las Palmas de Gran Canaria, Canary Islands, 35016, Spain

    Contact Phone: •••-•••-••••

  • Hospital Puerta de Hierro ( Site 1705)

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

    Contact Phone: •••-•••-••••

  • Hospital Universitario Virgen Macarena ( Site 1709)

    RECRUITING

    Seville, 41009, Spain

    Contact Phone: •••-•••-••••

  • Hospital Universitario la Paz ( Site 1710)

    RECRUITING

    Madrid, 28046, Spain

    Contact Phone: •••-•••-••••

  • Institut Català d'Oncologia (ICO) - Girona ( Site 1703)

    RECRUITING

    Girona, Gerona, 17007, Spain

    Contact Phone: •••-•••-••••

  • Instituto Alexander Fleming ( Site 0310)

    RECRUITING

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina

    Contact Phone: •••-•••-••••

  • Kartal Lütfi Kırdar Şehir Hastanesi ( Site 1826)

    RECRUITING

    Istanbul, 34865, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Keimyung University Dongsan Hospital ( Site 3605)

    RECRUITING

    Daegu, Taegu-Kwangyokshi, 42601, South Korea

    Contact Phone: •••-•••-••••

  • Liv Hospital Ankara ( Site 1828)

    RECRUITING

    Ankara, 6680, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 1902)

    RECRUITING

    Lviv, Lviv Oblast, 79059, Ukraine

    Contact Phone: •••-•••-••••

  • ME "Rivne Regional Antitumor Center" Rivne Regional Council ( Site 1912)

    RECRUITING

    Rivne, Rivne Oblast, 33010, Ukraine

    Contact Phone: •••-•••-••••

  • Mackay Memorial Hospital ( Site 3701)

    RECRUITING

    Taipei, 10449, Taiwan

    Contact Phone: •••-•••-••••

  • Medical Center "Mriya Med-Service" ( Site 1911)

    RECRUITING

    Kryvyi Rih, Dnipropetrovsk Oblast, 50000, Ukraine

    Contact Phone: •••-•••-••••

  • Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1915)

    RECRUITING

    Kyiv, 03057, Ukraine

    Contact Phone: •••-•••-••••

  • Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 1824)

    RECRUITING

    Mersin, 33240, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Metaxa Cancer Hospital of Piraeus ( Site 1207)

    RECRUITING

    Piraeus, Attica, 185 37, Greece

    Contact Phone: •••-•••-••••

  • Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 1914)

    RECRUITING

    Lutsk, Volyn Oblast, 43018, Ukraine

    Contact Phone: •••-•••-••••

  • Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council ( Site 1913)

    RECRUITING

    Odesa, Odesa Oblast, 65025, Ukraine

    Contact Phone: •••-•••-••••

  • National Cancer Center ( Site 3603)

    RECRUITING

    Goyang-si, Kyonggi-do, 10408, South Korea

    Contact Phone: •••-•••-••••

  • National Cheng Kung University Hospital ( Site 3706)

    RECRUITING

    Tainan, 704, Taiwan

    Contact Phone: •••-•••-••••

  • Ningbo No. 2 Hospital ( Site 2124)

    RECRUITING

    Ningbo, Zhejiang, 315010, China

    Contact Phone: •••-•••-••••

  • Peking Union Medical College Hospital ( Site 2105)

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-••••

  • Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 1916)

    RECRUITING

    Kropyvnytskyi, Kirovohrad Oblast, 25006, Ukraine

    Contact Phone: •••-•••-••••

  • Queen Mary Hospital ( Site 3100)

    RECRUITING

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-••••

  • Recep Tayyip Erdogan University Training and Research Hospital ( Site 1816)

    RECRUITING

    Rize, 53020, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

  • Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 1909)

    RECRUITING

    Chernivtsi, Chernivetska Oblast, 58013, Ukraine

    Contact Phone: •••-•••-••••

  • Sanatorio Parque ( Site 0311)

    RECRUITING

    Rosario, Santa Fe Province, S2000DSV, Argentina

    Contact Phone: •••-•••-••••

  • Severance Hospital Yonsei University Health System ( Site 3601)

    RECRUITING

    Seoul, 03722, South Korea

    Contact Phone: •••-•••-••••

  • Shalimov Institute of Surgery and Transplantation ( Site 1907)

    RECRUITING

    Kyiv, 03126, Ukraine

    Contact Phone: •••-•••-••••

  • Sichuan Cancer hospital ( Site 2101)

    RECRUITING

    Chengdu, Sichuan, 610000, China

    Contact Phone: •••-•••-••••

  • Sun Yat-sen University Cancer Center ( Site 2134)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-••••

  • Taipei Medical University Shuang Ho Hospital ( Site 3700)

    RECRUITING

    New Taipei City, 235, Taiwan

    Contact Phone: •••-•••-••••

  • The Catholic University of Korea St. Vincent s Hospital ( Site 3602)

    RECRUITING

    Suwon, Kyonggi-do, 16247, South Korea

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital Of Fujian Medical University ( Site 2123)

    RECRUITING

    Fuzhou, Fujian, 350005, China

    Contact Phone: •••-•••-••••

  • The Third Peoples Hospital Of Chengdu ( Site 2141)

    RECRUITING

    Chengdu, Sichuan, 610031, China

    Contact Phone: •••-•••-••••

  • Tri-Service General Hospital ( Site 3708)

    RECRUITING

    Taipei, 11490, Taiwan

    Contact Phone: •••-•••-••••

  • Ukrainian Center of Tomotherapy ( Site 1917)

    RECRUITING

    Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine

    Contact Phone: •••-•••-••••

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139)

    RECRUITING

    Wuhan, Hubei, 430048, China

    Contact Phone: •••-•••-••••

  • İnönü Üniversitesi Turgut Özal Tıp Merkezi ( Site 1815)

    RECRUITING

    Malatya, 44280, Turkey (Türkiye)

    Contact Phone: •••-•••-••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

calderasib (oral tablet) plus pembrolizumab and hyaluronidase (injection)

What this could lead to

If successful, this combination could help prevent lung cancer from coming back after surgery, offering a new option for people with a specific KRAS mutation.

What could go wrong

This is an early-stage Phase 3 trial, so results are not guaranteed. The added drug may cause side effects or not improve outcomes over standard treatment.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.